Free Trial
NASDAQ:ELEV

Elevation Oncology Q2 2023 Earnings Report

Elevation Oncology logo
$0.31 -0.01 (-3.23%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.31 +0.01 (+1.80%)
As of 05:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevation Oncology EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Elevation Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elevation Oncology Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 3, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Elevation Oncology's Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Elevation Oncology Earnings Headlines

Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
Elevation Oncology (ELEV) Gets a Hold from Leerink Partners
See More Elevation Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elevation Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elevation Oncology and other key companies, straight to your email.

About Elevation Oncology

Elevation Oncology (NASDAQ:ELEV), an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

View Elevation Oncology Profile

More Earnings Resources from MarketBeat